US Broker Ratings

Wave Life Sciences Ltd. (WVE) Stock Analysis: Biotechnology Innovator with 140% Upside Potential

Wave Life Sciences Ltd. (NASDAQ: WVE) is turning heads in the biotechnology sector with its cutting-edge approach to RNA medicine. Founded in 2012 and based in Singapore, Wave Life Sciences..

Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Uncovering a Potential 84.97% Upside in Biotech

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is making waves in the biotechnology sector, leveraging its innovative approach to drug discovery. The company’s focus on integrating biology, chemistry, automation, and data science..

Supernus Pharmaceuticals (SUPN) Stock Analysis: A 14.66% Upside and Strong Buy Ratings Shape Investor Outlook

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) offers investors a compelling prospect with a reported potential upside of 14.66%. As a specialty and generic drug manufacturer in the healthcare sector, Supernus focuses..

Mesoblast Limited (MESO) Investor Outlook: Exploring a 141% Potential Upside in Biotech

Mesoblast Limited (MESO), a pioneering biotechnology firm in the healthcare sector, presents a compelling opportunity for investors, especially with an impressive potential upside of 141.21% implied by the average analyst..

Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Evaluating the 17% Potential Upside for Healthcare Investors

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) stands out in the healthcare sector with its innovative approach to diabetes management. As a leading player in the medical devices industry, the company..

Phreesia, Inc. (PHR) Stock Analysis: Exploring a Potential 128% Upside in Healthcare SaaS

Phreesia, Inc. (PHR), a Wilmington, Delaware-based company, is making waves with its innovative SaaS-based software and payment platform tailored for the healthcare industry. Despite a challenging market environment, Phreesia’s stock..

MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a 34.94% Upside in the Biotech Sphere

MoonLake Immunotherapeutics (NASDAQ: MLTX), a Switzerland-based clinical-stage biotechnology firm, is capturing the attention of investors with a potential upside of 34.94%, according to analyst estimates. Specializing in the development of..

Evolent Health, Inc (EVH) Stock Analysis: Exploring a 44.65% Potential Upside in Health Information Services

Evolent Health, Inc (NASDAQ: EVH), a prominent player in the health information services sector, offers a unique proposition for investors seeking exposure to the burgeoning healthcare industry. With a market..

Veracyte, Inc. (VCYT) Stock Analysis: Uncovering a Promising 34.96% Upside for Investors

Veracyte, Inc. (VCYT), a prominent player in the healthcare sector, specifically within the diagnostics and research industry, stands as a compelling prospect for investors seeking exposure to innovative diagnostic solutions...

Kymera Therapeutics (KYMR) Stock Analysis: Exploring a 30% Upside Potential Amid Biotech Innovation

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a name that has been gaining traction in the biotechnology sector, particularly for its innovative approach to drug development. As a clinical-stage biopharmaceutical company,..

Liquidia Corporation (LQDA) Investor Outlook: Unveiling a 38.98% Potential Upside in the Biopharma Sphere

For investors with an eye on the biopharmaceutical sector, Liquidia Corporation (NASDAQ: LQDA) presents an intriguing opportunity. Operating within the niche of drug manufacturing, specializing in both specialty and generic..

Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Potential 142% Upside in the Biotech Arena

Dyne Therapeutics, Inc. (NASDAQ: DYN), a clinical-stage biotechnology company focused on neuromuscular diseases, has sparked investor interest with its promising pipeline and potential for substantial stock price appreciation. With a..

Innoviva, Inc. (INVA) Stock Analysis: With a 45% Potential Upside, Is It Time to Buy?

Innoviva, Inc. (NASDAQ: INVA) is making waves in the biotechnology sector with its compelling growth metrics, strategic partnerships, and a significant potential upside that individual investors might find hard to..

Aveanna Healthcare Holdings Inc (AVAH): Analyst Ratings Reveal 48% Potential Upside

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a prominent player in the U.S. medical care facilities industry, has garnered significant attention from investors due to its impressive growth trajectory and potential..

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a Promising 73.52% Potential Upside for Investors

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is gaining traction among investors in the healthcare sector, particularly those focused on biotechnology. With a market capitalization of $2.32 billion, this clinical-stage biopharmaceutical company..

Merus N.V. (MRUS) Stock Analysis: A Look at Its 7.78% Potential Upside in the Biotech Arena

Merus N.V. (NASDAQ: MRUS), a prominent player in the biotechnology sector, is capturing investor attention with its innovative approach to antibody therapeutics. Headquartered in the Netherlands, Merus is solidifying its..

Integra LifeSciences Holdings C (IART) Stock Analysis: Evaluating a 45% Upside Potential Amidst Market Challenges

Integra LifeSciences Holdings Corporation (NASDAQ: IART) remains a notable player in the healthcare sector, specifically within the medical devices industry. Headquartered in Princeton, New Jersey, Integra focuses on manufacturing and..

Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Potential 36% Upside for Investors in Pain Management Solutions

Investors focusing on the healthcare sector may find Pacira BioSciences, Inc. (NASDAQ: PCRX) a compelling option, particularly given the company’s strong foothold in non-opioid pain management solutions. With a market..

Disc Medicine, Inc. (IRON) Stock Analysis: A 50% Potential Upside in the Biotech Sector

Disc Medicine, Inc. (NASDAQ: IRON) stands out in the healthcare sector with a promising outlook in the biotechnology industry. Despite its current trading price of $66.54, the company offers a..

Ocular Therapeutix, Inc. (OCUL) Stock Analysis: 136% Potential Upside Captivates Investor Interest

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a prominent player in the biotechnology sector, is capturing the attention of investors with its promising portfolio and remarkable potential upside. Headquartered in Bedford, Massachusetts,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds